Y-mAbs Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.16) Estimate, Sales $19.931M Miss $22.220M Estimate
Y-mAbs Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.16) Estimate, Sales $19.931M Miss $22.220M Estimate
Y-mabs Therapeutics 2024年第一季度GAAP每股收益美元（0.15美元）超過預期（0.16美元），銷售額爲1,93.1萬美元，低於預期的22220萬美元
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $19.931 million which missed the analyst consensus estimate of $22.220 million by 10.30 percent. This is a 1.58 percent decrease over sales of $20.251 million the same period last year.
Y-mabs Therapeutics（納斯達克股票代碼：YMAB）公佈的季度虧損爲每股0.15美元，比分析師共識估計的美元（0.16美元）高出6.25％。這與去年同期相比沒有變化。該公司公佈的季度銷售額爲1993.1萬美元，比分析師普遍預期的222.2萬美元低10.30％。這比去年同期的2,0251萬美元的銷售額下降了1.58％。